Onechain Immunotherapeutics is a clinical stage biotech company based in Barcelona (Spain) and focused in the development of CAR T therapies for the treatment of oncological diseases.

Our lead program is a novel and selective CAR T therapy against CD1a (OC-1) for the treatment of refractory/relapsed patients with cortical T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (co T-ALL), a T-ALL subgroup without many options to date. OC-1 demonstrated strong preclinical safety and efficacy and is currently under evaluation in a phase 1 clinical trial to assess the safety and efficacy of the therapy (CARxALL clinical trial).

OC-1 has been granted Orphan Drug Designation for ALL by the EMA and the FDA.